Treatment of Diabetes in People with Heart Failure

Canadian Journal of Diabetes

Volumn 37, Issue SUPPL.1, 2013, Pages

  Howlett, Jonathan G ^a   MacFadyen, John C ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCOSYLATED HEMOGLOBIN; METFORMIN; METOPROLOL;

ARTICLE; CARDIOVASCULAR RISK; CAUSAL ATTRIBUTION; DIABETES MELLITUS; DRUG CHOICE; DRUG EFFICACY; ECHOCARDIOGRAPHY; GLYCEMIC CONTROL; HEART FAILURE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LACTIC ACIDOSIS; MICROALBUMINURIA; PREVALENCE; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; THORAX RADIOGRAPHY; TREATMENT RESPONSE; CANADA; COMPLICATION; DIABETES MELLITUS, TYPE 2; PRACTICE GUIDELINE;

CANADA; DIABETES MELLITUS, TYPE 2; HEART FAILURE; HUMANS;

EID: 84876043117     PISSN: 14992671     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcjd.2013.01.036     Document Type: Article

References (31)

1. Albertini J.-P., Cohen R., Valensi P., et al. B-type natriuretic peptide, a marker of asymptomatic left ventricular dysfunction in type 2 diabetic patients. Diabetes Metab 2008, 34:355-362.
2. O'Donoghue M., Kenney P., Oestreicher E., et al. Usefulness of aminoterminal pro-brain natriuretic peptide testing for the diagnostic and prognostic evaluation of dyspneic patients with diabetes mellitus seen in the emergency department (from the PRIDE Study). Am J Cardiol 2007, 100:1336-1340.
3. Valle R., Bagolin E., Canali C., et al. The BNP assay does not identify mild left ventricular diastolic dysfunction in asymptomatic diabetic patients. Eur J Echocardiogr 2006, 7:40-44.
4. Shimabukuro M., Higa N., Oshiro Y., et al. Diagnostic utility of brain-natriuretic peptide for left ventricular diastolic dysfunction in asymptomatic type 2 diabetic patients. Diabetes Obes Metab 2007, 9:323-329.
5. Galderisi M. Diastolic dysfunction and diabetic cardiomyopathy: evaluation by Doppler echocardiography. J Am Coll Cardiol 2006, 48:1548-1551.
6. Karavanaki K., Kazianis G., Konstantopoulos I., et al. Early signs of left ventricular dysfunction in adolescents with Type 1 diabetes mellitus: the importance of impaired circadian modulation of blood pressure and heart rate. J Endocrinol Invest 2008, 31:289-296.
7. Grandi A.M., Piantanida E., Franzetti I., et al. Effect of glycemic control on left ventricular diastolic function in type 1 diabetes mellitus. Am J Cardiol 2006, 97:71-76.
8. Ng A.C.T., Delgado V., Bertini M., et al. Findings from left ventricular strain and strain rate imaging in asymptomatic patients with type 2 diabetes mellitus. Am J Cardiol 2009, 104:1398-1401.
9. Mishra T.K., Rath P.K., Mohanty N.K., Mishra S.K. Left ventricular systolic and diastolic dysfunction and their relationship with microvascular complications in normotensive, asymptomatic patients with type 2 diabetes mellitus. Indian Heart J 2008, 60:548-553.
10. Ashraf S.M.S., Basir F. Association of hypertension and diastolic dysfunction with type-2 diabetes mellitus. Pakistan J Med Sci 2007, 23:344-348.
11. Stahrenberg R., Edelmann F., Mende M., et al. Association of glucose metabolism with diastolic function along the diabetic continuum. Diabetologia 2010, 53:1331-1340.
12. Dinh W., Futh R., Lankisch M., et al. Cardiovascular autonomic neuropathy contributes to left ventricular diastolic dysfunction in subjects with Type 2 diabetes and impaired glucose tolerance undergoing coronary angiography. Diabet Med 2011, 28:311-318.
13. From A.M., Scott C.G., Chen H.H. Changes in diastolic dysfunction in diabetes mellitus over time. Am J Cardiol 2009, 103:1463-1466.
14. Aguilar D., Deswal A., Ramasubbu K., et al. Comparison of patients with heart failure and preserved left ventricular ejection fraction among those with versus without diabetes mellitus. Am J Cardiol 2010, 105:373-377.
15. Ghali J.K., Boehmer J., Feldman A.M., et al. Influence of diabetes on cardiac resynchronization therapy with or without defibrillator in patients with advanced heart failure. J Card Fail 2007, 13:769-773.
16. Fantoni C., Regoli F., Ghanem A., et al. Long-term outcome in diabetic heart failure patients treated with cardiac resynchronization therapy. Eur J Heart Fail 2008, 10:298-307.
17. Haas S.J., Vos T., Gilbert R.E., et al. Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J 2003, 146:848-853.
18. Lopes R.J., Lourenco A.P., Mascarenhas J., et al. Safety of spironolactone use in ambulatory heart failure patients. Clin Cardiol 2008, 31:509-513.
19. Desai A.S., Swedberg K., McMurray J.J.V., et al. Incidence and predictors of hyperkalemia in patients with heart failure. An analysis of the CHARM program. J Am Coll Cardiol 2007, 50:1959-1966.
20. Sadjadi S.A., McMillan J.I., Jaipaul N., et al. A comparative study of the prevalence of hyperkalemia with the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers. Ther Clin Risk Manage 2009, 5:547-552.
21. Phillips C.O., Kashani A., Ko D.K., et al. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch Intern Med 2007, 167:1930-1936.
22. Raebel M.A., McClure D.L., Chan K.A., et al. Laboratory evaluation of potassium and creatinine among ambulatory patients prescribed spironolactone: are we monitoring for hyperkalemia?. Ann Pharmacother 2007, 41:193-200.
23. Raebel M.A., Ross C., Xu S., et al. Diabetes and drug-associated hyperkalemia: Effect of potassium monitoring. J Gen Intern Med 2010, 25:326-333.
24. Feuvray D., Darmellah A. Diabetes-related metabolic perturbations in cardiac myocyte. Diabetes Metab 2008, 34(suppl 1):3-9.
25. Wenmeng W., Qizhu T. Early administration of trimetazidine may prevent or ameliorate diabetic cardiomyopathy. Med Hypotheses 2011, 76:181-183.
26. Belardinelli R., Cianci G., Gigli M., et al. Effects of trimetazidine on myocardial perfusion and left ventricular systolic function in type 2 diabetic patients with ischemic cardiomyopathy. J Cardiovasc Pharmacol 2008, 51:611-615.
27. Bell D.S., Lukas M.A., Holdbrook F.K., et al. The effect of carvedilol on mortality risk in heart failure patients with diabetes: results of a meta-analysis. Curr Med Res Opin 2006, 22:287-296.
28. Salpeter S., Greyber E., Pasternak G., Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010, (4). CD 002967.
29. Salpeter S.R., Greyber E., Pasternak G.A., Salpeter E.E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Arch Intern Med 2003, 163:2594-2602.
30. Andersson C., Olesen J.B., Hansen P.R., et al. Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: retrospective nationwide cohort study. Diabetologia 2010, 53:2546-2553.
31. Arnold J.M.O., Howlett J.G., Dorian P., et al. Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. Can J Cardiol 2007, 23:21-45.